Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1896–1898. doi: 10.1128/aac.39.8.1896

Timing of penicillin treatment influences the course of Streptococcus pneumoniae-induced middle ear inflammation.

K Sato 1, M K Quartey 1, C L Liebeler 1, G S Giebink 1
PMCID: PMC162851  PMID: 7486944

Abstract

Penicillin treatment timing, using the chinchilla pneumococcal otitis media model, was investigated. Early treatment (when approximately 10(3) pneumococcal CFU/ml was present in middle ear fluid) significantly accelerated inflammatory-cell influx, whereas late treatment (with approximately 10(7) pneumococcal CFU/ml present in middle ear fluid) did not. Therefore, antiinflammatory interventions will be needed early in the course of inflammation.

Full Text

The Full Text of this article is available as a PDF (209.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bluestone C. D., Stephenson J. S., Martin L. M. Ten-year review of otitis media pathogens. Pediatr Infect Dis J. 1992 Aug;11(8 Suppl):S7–11. doi: 10.1097/00006454-199208001-00002. [DOI] [PubMed] [Google Scholar]
  2. Canafax D. M., Nonomura N., Erdmann G. R., Le C. T., Juhn S. K., Giebink G. S. Experimental animal models for studying antimicrobial pharmacokinetics in otitis media. Pharm Res. 1989 Apr;6(4):279–285. doi: 10.1023/a:1015938205892. [DOI] [PubMed] [Google Scholar]
  3. Carlsen B. D., Kawana M., Kawana C., Tomasz A., Giebink G. S. Role of the bacterial cell wall in middle ear inflammation caused by Streptococcus pneumoniae. Infect Immun. 1992 Jul;60(7):2850–2854. doi: 10.1128/iai.60.7.2850-2854.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Giebink G. S., Berzins I. K., Quie P. G. Animal models for studying pneumococcal otitis media and pneumococcal vaccine efficacy. Ann Otol Rhinol Laryngol Suppl. 1980 May-Jun;89(3 Pt 2):339–343. doi: 10.1177/00034894800890s380. [DOI] [PubMed] [Google Scholar]
  5. Giebink G. S., Juhn S. K., Weber M. L., Le C. T. The bacteriology and cytology of chronic otitis media with effusion. Pediatr Infect Dis. 1982 Mar-Apr;1(2):98–103. doi: 10.1097/00006454-198203000-00007. [DOI] [PubMed] [Google Scholar]
  6. Giebink G. S. The microbiology of otitis media. Pediatr Infect Dis J. 1989 Jan;8(1 Suppl):S18–S20. [PubMed] [Google Scholar]
  7. Holloway Y., Boersma W. G., Kuttschrütter H., Snijder J. A. Detection of pneumococcal capsular antigen in the presence of penicillin in vitro. Scand J Infect Dis. 1993;25(3):317–322. doi: 10.3109/00365549309008505. [DOI] [PubMed] [Google Scholar]
  8. Kawana M., Kawana C., Giebink G. S. Penicillin treatment accelerates middle ear inflammation in experimental pneumococcal otitis media. Infect Immun. 1992 May;60(5):1908–1912. doi: 10.1128/iai.60.5.1908-1912.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leinonen M. K. Detection of Pneumococcal Capsular polysaccharide antigens by latex agglutination, counterimmunoelectrophoresis, and radioimmunoassay in middle ear exudates in acute otitis media. J Clin Microbiol. 1980 Feb;11(2):135–140. doi: 10.1128/jcm.11.2.135-140.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nonomura N., Giebink G. S., Juhn S. K., Harada T., Aeppli D. Pathophysiology of Streptococcus pneumoniae otitis media: kinetics of the middle ear biochemical and cytologic host responses. Ann Otol Rhinol Laryngol. 1991 Mar;100(3):236–243. doi: 10.1177/000348949110000313. [DOI] [PubMed] [Google Scholar]
  11. Nonomura N., Giebink G. S., Zelterman D., Harada T., Juhn S. K. Middle ear fluid lysozyme source in experimental pneumococcal otitis media. Ann Otol Rhinol Laryngol. 1991 Jul;100(7):593–596. doi: 10.1177/000348949110000715. [DOI] [PubMed] [Google Scholar]
  12. Ripley-Petzoldt M. L., Giebink G. S., Juhn S. K., Aeppli D., Tomasz A., Tuomanen E. The contribution of pneumococcal cell wall to the pathogenesis of experimental otitis media. J Infect Dis. 1988 Feb;157(2):245–255. doi: 10.1093/infdis/157.2.245. [DOI] [PubMed] [Google Scholar]
  13. Tuomanen E., Hengstler B., Rich R., Bray M. A., Zak O., Tomasz A. Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis. J Infect Dis. 1987 May;155(5):985–990. doi: 10.1093/infdis/155.5.985. [DOI] [PubMed] [Google Scholar]
  14. Tuomanen E., Liu H., Hengstler B., Zak O., Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis. 1985 May;151(5):859–868. doi: 10.1093/infdis/151.5.859. [DOI] [PubMed] [Google Scholar]
  15. Tuomanen E., Tomasz A., Hengstler B., Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis. 1985 Mar;151(3):535–540. doi: 10.1093/infdis/151.3.535. [DOI] [PubMed] [Google Scholar]
  16. Täuber M. G., Kunz S., Zak O., Sande M. A. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1989 Apr;33(4):418–423. doi: 10.1128/aac.33.4.418. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES